Medical Condition

interstitial lung disease

Total Trials

10

Recruiting Now

10

Trial Phases

Phase 2

Pulmonary clinical trials span chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and rare ILDs β€” each with distinct pathophysiology and treatment targets. IPF research is particularly active, building on pirfenidone and nintedanib to identify anti-fibrotic combinations that slow disease more effectively.

Trials include inhaled triple combinations for COPD (LABA/LAMA/ICS), treprostinil subcutaneous for PAH, PDE4B inhibitors, anti-CCL2 antibodies for fibrosis, and aerosol gene therapy for CF (CFTR modulators plus mRNA). FEV1, 6-minute walk distance, and lung function decline remain core endpoints with patient-reported outcomes gaining weight.

Frequently Asked Questions — interstitial lung disease Clinical Trials

How many clinical trials are currently recruiting for interstitial lung disease?

ClinicalMetric currently tracks 10 actively recruiting clinical trials for interstitial lung disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 10. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for interstitial lung disease?

interstitial lung disease research spans Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a interstitial lung disease clinical trial?

Eligibility criteria for interstitial lung disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 2

Top Sponsors

Mayo Clinic 1 trial

Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1 trial

University Hospital Southampton NHS Foundation Trust 1 trial

Paul Szabolcs 1 trial

University of Rochester 1 trial

Recruiting Clinical Trials

NCT03478826

Recruiting

Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

Ultrasound and Respiratory Physiological Signals in Lung Diseases

Fondazione Policlinico Univers...

View Trial →

NCT06488638

Recruiting

Pilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF)

University Hospital Southampto...

View Trial →

NCT03630211 Phase 2

Recruiting

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease

University of Rochester

View Trial →

NCT07323732 Phase 2

Recruiting

A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease

Memorial Sloan Kettering Cance...

View Trial →

NCT04095351

Recruiting

Connective Tissue Diseases and Lung Manifestations

Medical University Innsbruck

View Trial →

NCT05681962

Recruiting

Practice of Oxygenation and Respiratory Support During Fiberoptic Bronchoscopy

University Magna Graecia

View Trial →

NCT06325696 Phase 2

Recruiting

H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

National Institute of Environm...

View Trial →

NCT06087692

Recruiting

Efficacy of Video-Based Interactive Game Therapy in Interstitial Lung Patients

Related Conditions

idiopathic pulmonary fibrosis (2) systemic sclerosis (2) pulmonary hypertension (2) interstitial lung diseases (1) interstitial pneumonia (1) chronic obstructive pulmonary disease (1) emphysema or copd (1) ultrasonography (1) ultrasound imaging (1) ultrasound (1) diffuse sclerosis systemic (1) nsclc (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology